糖尿病与 COVID-19：疾病管理人群。
Diabetes and COVID-19 : Disease-Management-People.
机构信息
Third Department of Medicine with Metabolic Diseases and Nephrology, Hietzing Hospital with Neurological Center Rosenhuegel, Wolkersbergenstraße 1, 1130, Vienna, Austria.
Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Hietzing Hospital with Neurological Center Rosenhuegel, Vienna, Austria.
出版信息
Wien Klin Wochenschr. 2020 Jul;132(13-14):356-361. doi: 10.1007/s00508-020-01672-3. Epub 2020 May 20.
The current pandemic of SARS-CoV‑2 coronavirus disease 2019 (COVID-19) is a particular challenge for diabetes patients. Diabetes mellitus predisposes to a particularly severe course of the disease and doubles the COVID-19 mortality risk due to pulmonary and cardiac involvement. In addition, diabetes patients often suffer from comorbidities which further worsen clinical outcomes. Glycemic control during infectious diseases is often suboptimal, and antidiabetic drugs and insulin therapy have to be adapted accordingly. On the other hand, access of diabetes patients to outpatient clinics are limited during the ongoing season urging alternative treatment options, particularly the implementation of novel telemedicine strategies. Hence, the opportunity of the COVID 19 crisis should be taken to make a significant step forward in the care for diabetes patients.
当前的 2019 年严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的冠状病毒疾病（COVID-19）大流行，对糖尿病患者来说是一个特别的挑战。糖尿病使疾病的严重程度更为特殊，并且由于肺部和心脏受累，COVID-19 的死亡率风险增加一倍。此外，糖尿病患者经常患有合并症，这进一步恶化了临床结果。在传染病期间，血糖控制通常不理想，必须相应调整抗糖尿病药物和胰岛素治疗。另一方面，在当前季节，糖尿病患者门诊就诊受到限制，这促使需要替代治疗方案，特别是实施新的远程医疗策略。因此，应该利用 COVID-19 危机的机会，在糖尿病患者的护理方面迈出重要一步。
Zotero 插件